27 MarMember of Parliament Duke Lefhoko announced on Friday.

Botswana legislators Plan publication of the report Gauging Public Opinion on national response to HIV / AIDSlegislators the end of December scheduled at the end of December, for a report on the recent hearings to the public’s views on HIV / AIDS issues in the doctrine sought to share land, Member of Parliament Duke Lefhoko announced on Friday, reports Mmegi Botswana.

In the lab now has built in the UK originally have been confirmed has been confirmed to work on fusion. By recreating in miniature a tiny piece of the Solar Wind scientists were confirmed in the laboratory in a position that a small hole in the solar wind is all that’s required a leading researcher would the astronauts safe on their journey to our nearest neighbor, Ruth Bamford, a leading researcher at the Rutherford Appleton Laboratory, said: These initial experiments have shown promise and that it may be possible to protect astronauts from deadly space weather .INSPIRE was a randomized, double-blind, Placebo – controlled Phase 3 trial evaluating of safety and efficacy Actimmune in IPF patients with light evaluate moderating and moderate impairment of lung function. The primary endpoint had the survival. The lack of utility limits stop has been developed to allow of early the end study to event information was not statistically the Interim. With clinically major treatment effect of Actimmune InterMune plans. The data of Phase 3 INSPIRE study submit for presentation at an fair medical congress and for publication in a peer-reviewed journal The intermediate results the INSPIRE trial and our decision to stop the process disappointing, said Steve Porter, Chief Medical Officer of at InterMune said. We are grateful for the strong support that we obtain from physicians, healthcare providers and above all the patients who participated at the clinical evaluation of Actimmune .

Ltd. We are also focused on the development of our innovative hepatitis C viral drug candidate ITMN – one hundred and ninety first in cooperation with our partner Rochester our period 1 a study ITMN-191 be progressing as planned ‘.. Dan Welch, expect and Chief Executive Officer from InterMune in, said, ‘Although we are is this conclusion were Actimmune frustrated, we commit ourselves to addressing the significant unmet medical requirements remain at IPF with pirfenidone with our Phase 3 CAPACITY Programme One positive effect.